Quick answer
Educational reconstitution and measurement guide for tirzepatide research vials (10mg, 20mg, 30mg). Covers BAC water volumes, U-100 unit math, and a slow weekly step-up schedule. CoreVials materials are for laboratory research only, not for human or animal use.
Tirzepatide is a dual agonist. It hits two incretin receptors: GLP-1 and GIP. In plain terms, research and clinical programs study it for appetite control, glycemic markers, and body-composition endpoints more strongly than single GLP-1 tools in head-to-head trial settings.
This walkthrough covers vial mix math, storage basics, and a conservative example titration so the numbers stay clear on a phone.
Related tools: the reconstitution calculator, vial pages for 10mg and 30mg, plus the retatrutide beginner guide if you are comparing triple-agonist math.
Understanding your vial size
Bigger vials hold more total compound. They do not change the chemistry. They only change how long one vial lasts at a given weekly amount.
Best early on while weekly amounts stay near 2.5-5 mg. Often covers the first escalation blocks.
Good middle option once you are holding 5-10 mg weekly for longer stretches.
Fewer reconstitutions over a longer run, including higher weekly amounts toward 12.5-15 mg.
How much BAC water to add
Bacteriostatic water (BAC water) is sterile water with a small amount of benzyl alcohol preservative. The volume you add sets concentration (mg per ml). Higher concentration = fewer syringe units for the same mg amount.
Quick volume check: on a U-100 syringe, 100 units = 1 ml. So 25 units is only 0.25 ml of fluid. That is a small subcutaneous volume even if the unit number looks big.
For larger vials, we recommend a stronger mix so early 2.5 mg draws stay closer to 12-13 units instead of 25.
10mg vial
U-100 syringe marks
- 25 u=2.5 mg
- 50 u=5 mg
- 75 u=7.5 mg
- 100 u=10 mg
Best simple starter mix. 2.5 mg = 25 units = 0.25 ml. Clean whole-unit marks. Do not go below 1 ml on a 10mg vial if you want easy 2.5 mg math.
20mg vial
U-100 syringe marks
- 12.5 u=2.5 mg
- 25 u=5 mg
- 37.5 u=7.5 mg
- 50 u=10 mg
1 ml keeps draws smaller: 2.5 mg is 12.5 units (halfway between 12 and 13 on most U-100 syringes). 15 mg = 75 units. Alternate 2 ml = 10 mg/ml if you prefer the 25-unit starter mark.
30mg vial
U-100 syringe marks (same as 20mg / 1 ml)
- 12.5 u=2.5 mg
- 25 u=5 mg
- 37.5 u=7.5 mg
- 50 u=10 mg
1.5 ml is the sweet spot: same 20 mg/ml chart as the 20mg / 1 ml mix, so unit marks stay familiar. 15 mg = 75 units. Alternate 2 ml = 15 mg/ml (2.5 mg ≈ 17 units, 5 mg ≈ 33 units, 7.5 mg = 50 units, 15 mg = 100 units) if you want a rounder BAC volume.
Step-by-step reconstitution
- 1Warm up briefly: Let the vial sit 15-20 minutes so it is not ice-cold.
- 2Clean stoppers: Wipe the rubber top with alcohol and let it dry.
- 3Draw BAC water: Pull your planned volume into a sterile syringe.
- 4Inject slowly: Aim at the glass wall, not directly onto the powder.
- 5Swirl gently: Circular rolls only. Do not shake.
- 6Wait: Give it a few minutes. The solution should look clear and colorless.
- 7Store cold: Refrigerate at about 2-8 C. Many labs plan around 28 days after reconstitution with bacteriostatic water and clean technique.
If the mix stays cloudy after gentle swirling, do not force it. Recheck technique and sourcing.
Example weekly step-up schedule
Educational references usually start low and increase every 4 weeks. This matches the common 2.5 mg step pattern discussed in clinical protocols. It is example measurement math, not a personal prescription.
Hold the full block. Mild appetite change and early GI adaptation are common here.
First bump. Cravings and portion size often drop more clearly in this window.
Moderate hold. Stay here longer if tolerance is still settling.
Common longer-term holding point for many protocols.
Optional step. Only if 10 mg has plateaued and sides stay manageable.
Upper end of commonly discussed weekly schedules. Higher is not automatic.
At the recommended 10mg / 1 ml mix (10 mg/ml): 2.5 mg = 25 units, 5 mg = 50 units, 7.5 mg = 75 units, 10 mg = 100 units.
At the recommended 20mg / 1 ml or 30mg / 1.5 ml mixes (20 mg/ml): 2.5 mg = 12.5 units, 5 mg = 25 units, 7.5 mg = 37.5 units, 10 mg = 50 units, 15 mg = 75 units.
What to expect by stage
- Weeks 1-4: Early appetite quieting. Mild nausea or fullness can show up while you adapt.
- Weeks 5-8: Stronger craving control and steadier weekly changes for many people in trial-style reports.
- Weeks 9-16: Clearer body-composition shifts if protein, hydration, and meal size stay intentional.
- Week 16+: Longer holds matter more than constant escalation. Metabolic markers in clinical reports often keep improving with consistency.
For food and hydration habits when appetite drops, see protein, hydration, and side-effect basics.
Injection basics
- Where: Subcutaneous fat areas such as abdomen (a couple inches from the navel), thigh, or upper arm.
- When: Same day each week. Consistency matters more than clock time.
- Rotate sites: Do not use the exact same spot back to back.
- Needle: Common lab supply choice is a 29-31 gauge insulin syringe with a short needle.
Common beginner mistakes
- Skipping the 2.5 mg hold: Jumping straight to 5 mg+ in week 1 is a frequent cause of rough GI weeks.
- Shaking the vial: Can damage peptides. Swirl or roll only.
- Skipping refrigeration: Reconstituted solution should stay cold.
- Stacking other GLP-1 pathway agonists: Semaglutide or retatrutide on top usually raises side-effect load without a clean additive story.
- Ignoring protein: Quieter hunger can cut protein intake too hard if you are not intentional.
Side effects and practical habits
- Nausea: Most common. Smaller meals, less heavy fat at once, slower eating.
- Diarrhea or constipation: Often shows up during escalations. Fiber, fluids, and meal timing help.
- Early satiety / vomiting risk at bumps: Hold the current block longer instead of rushing the next step.
- Injection-site redness: Usually mild. Rotate sites and clean with alcohol.
- Early fatigue: Electrolytes and protein matter when calories drop.
Stop-signal symptoms (severe abdominal pain, persistent vomiting, signs of dehydration) need clinical attention. This page is educational measurement math, not triage advice.
Research-use reminder
- CoreVials tirzepatide is sold for laboratory research only
- This page is educational measurement math, not medical advice
- Do not stack multiple GLP-1 pathway agonists in the same protocol without a clear research rationale
FAQ
Can I use plain saline instead of bacteriostatic water?
For multi-draw refrigerated use, bacteriostatic water is the usual research supply choice because the preservative slows bacterial growth. Plain saline has no preservative and can also cause precipitation issues with some peptide workflows.
How do I know the reconstituted solution still looks usable?
It should stay clear and colorless. Cloudiness, particles, or color change are stop signals. With clean technique and refrigeration, many educational references plan around about 28 days.
Is tirzepatide the same idea as retatrutide?
No. Tirzepatide is dual (GLP-1 + GIP). Retatrutide adds glucagon-receptor activity on top of that pathway set. Different tools, different titration math. See the retatrutide guide for the triple-agonist version.
Can tirzepatide be stacked with semaglutide or retatrutide?
They share GLP-1 receptor activity. Stacking incretin agonists usually raises side-effect load. Pick one pathway tool for a given protocol.
What if a weekly dose is missed?
Educational references usually say take it when remembered, then resume the normal weekday. Do not double the next draw to catch up.
Track the basics
- Weekly weight (same day, same conditions)
- Waist / hip / chest measurements
- Side effects (what, when, how strong)
- Rough food and protein intake notes
Need help with unit math on another mix? Use the visual reconstitution calculator.
Bottom line
- 10mg vial: 1 ml BAC water (10 mg/ml) → 2.5 mg = 25 units
- 20mg vial: 1 ml BAC water (20 mg/ml) → 2.5 mg = 12.5 units
- 30mg vial: 1.5 ml BAC water (20 mg/ml) → 2.5 mg = 12.5 units
- Start low: hold 2.5 mg for weeks 1-4, then bump every 4 weeks
- Common ceiling: 15 mg / week in educational schedules
- Write it down: data beats guessing
References
- Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. NEJM
- ClinicalTrials.gov. SURMOUNT and related tirzepatide obesity / diabetes programs.
- Coskun, T., et al. (2018). LY3298176 (tirzepatide), a novel dual GIP and GLP-1 receptor agonist. Molecular Metabolism.
